SCHEMBL7686463

SCHEMBL7686463

COC(=O)[C@](C)(NC(=O)c1c(C)c(-c2ccccc2)nc2ccccc12)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
PDE10A Q9Y233 2/20 0.56
TACR3 P29371 5/20 0.56
DHODH Q02127 2/20 0.54
TACR2 P21452 2/20 0.52
ALDH1A1 P00352 2/20 0.52
MEN1 O00255 1/20 0.52
TP53 P04637 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
NFKB1 P19838 1/20 0.52
MAPK1 P28482 1/20 0.52
CYP2C19 P33261 1/20 0.52
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52
KMT2A Q03164 1/20 0.52
ATM Q13315 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7686462 1.00 TSHR (0.56) TSHRPDE10ATACR3DHODHTACR2
SCHEMBL8249659 0.89 PDE10A (0.59) TSHRPDE10ATACR3DHODHTACR2
SCHEMBL7684676 0.77 TACR3 (0.74) TSHRPDE10ATACR3TACR2ALDH1A1
SCHEMBL7684672 0.77 TACR3 (0.74) TSHRPDE10ATACR3TACR2ALDH1A1
SCHEMBL2372674 0.77 PDE10A (0.73) TSHRPDE10ATACR3DHODHTACR2
SCHEMBL2007335 0.76 CYP2D6 (0.62) TSHRPDE10ATACR3DHODHALDH1A1
SCHEMBL2053743 0.75 TACR3 (0.58) TSHRPDE10ATACR3DHODHCYP3A4
SCHEMBL2013005 0.74 TACR3 (0.59) TSHRPDE10ATACR3TACR2TP53
SCHEMBL5945357 0.73 PDE10A (0.68) TSHRPDE10ATACR3DHODHTACR2
SCHEMBL1581468 0.73 PDE10A (1.00) TSHRPDE10ADHODHCYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020068827-A1 Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists SMITHKLINE BEECHAM S.P.A. 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068827-A1 Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists TAC3, TACR2, TACR1 TSHR 831/4885PDE10A 3087/4885TACR3 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.